Scientists have discovered a protein that enables bacteria to shut down into dormant spores under extreme conditions. The ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an ...

Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...